Gen-Wealth Partners’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.93K Hold
10
– – ﹤0.01% 692
2026
Q2
$700 Sell
10
-15
-60% -$776 ﹤0.01% 681
2026
Q1
$1.27K Hold
25
– – ﹤0.01% 663
2025
Q4
$737 Hold
25
– – ﹤0.01% 650
2025
Q3
$646 Hold
25
– – ﹤0.01% 644
2025
Q2
$690 Hold
25
– – ﹤0.01% 599
2025
Q1
$709 Hold
25
– – ﹤0.01% 577
2024
Q4
$1.04K Hold
25
– – ﹤0.01% 602
2024
Q3
$1.37K Hold
25
– – ﹤0.01% 609
2024
Q2
$2.97K Hold
25
– – ﹤0.01% 565
2024
Q1
$2.66K Hold
25
– – ﹤0.01% 556

Other funds holding MRNA

Gen-Wealth Partners's MRNA Position: Q3 2026 in Review

Gen-Wealth Partners held its Moderna (MRNA) position steady in Q3 2026 at 10 shares worth $1.93K. The position accounts for ﹤0.01% of the portfolio, ranked #692.

Gen-Wealth Partners first reported a position in MRNA in Q1 2024 and has held it in 11 quarters since. The position peaked at $2.97K in Q2 2024. 1,053 funds tracked by Wall St. Rank hold MRNA as of Q3 2026.

  • Gen-Wealth Partners held 10 shares of Moderna worth $1.93K as of Q3 2026.
  • Gen-Wealth Partners left its Moderna share count unchanged in Q3 2026.
  • Moderna made up ﹤0.01% of Gen-Wealth Partners's portfolio in Q3 2026, its #692 holding.
  • Gen-Wealth Partners first reported a position in Moderna in Q1 2024 and has held it in 11 quarters since.
  • Gen-Wealth Partners's Moderna position peaked at $2.97K in Q2 2024.
  • 1,053 funds tracked by Wall St. Rank held Moderna as of Q3 2026.

Based on Gen-Wealth Partners's 13F filing for Q3 2026, filed 4 Nov 2026.